FDA & EMA Recommend No New Patients for Lilly Sarcoma Drug After Trial Flops


Alaric Dearment writing for MedCity News reports that Eli Lilly announced last week that their phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in phase II study that led to its accelerated approval. The phase II study had 133 patients in 25 different subtypes of metastatic STS—showed Lartruvo and doxorubicin prolonged overall survival and progression-free survival compared with doxorubicin alone. However, phase III study results recently announced did not support the same findings. Lilly has suspended promotion of the drug.